Magani
Advanced Neurotrophic factor far
Menene ƙwayoyin rigakafi?
Kwayoyin rigakafi suna nufin rukuni a cikin jikin mutum na musamman a "kare." Wanda aka fi sani da fararen jini, ƙwayoyin rigakafi sun haɗa da lymphocytes daban-daban da phagocytes waɗanda zasu iya ganewa da kawar da antigens, suna shiga cikin martani na rigakafi. Jikinmu yana kama da ƙasa mai cin gashin kanta, kuma tsarin rigakafi yana aiki azaman soja da 'yan sanda. Ba wai kawai yana aiki azaman soja bane don ganowa da kawar da ƙwayoyin cuta masu mamayewa amma kuma yana aiki azaman 'yan sanda don ganewa da kawar da gurɓatattun ƙwayoyin cuta, masu mutuwa, ko wasu abubuwa masu cutarwa a cikin jiki.
Ayyukan ƙwayoyin rigakafi
Haɓaka rigakafi:Kunna tsarin rigakafi don inganta ikon yaƙar kamuwa da ƙwayoyin cuta da ƙwayoyin cuta.
Inganta Lafiya Mafi Kyau:Daidaita tsarin rigakafi don yin tsayayya da cututtuka da ƙwayoyin cuta, inganta ƙarfin ƙwayar salula, da kuma inganta lafiyar gabaɗaya.
Maganin tsufa:Haɓaka metabolism, da sauri kawar da matattu da ƙwayoyin tsufa don jinkirta tsufa.
Kariya da Magani:Ƙarfafa ƙarfin jiki don tsayayya da ciwace-ciwacen ƙwayoyi, a kan lokaci yana share ƙwayoyin da suka canza, don haka hanawa da kai hari ga ƙwayoyin tumor.
NK Cell
Yawan Jama'a:Inganta lafiyar rashin lafiya / farkon tsufa; rigakafin tiyata bayan tumor.
Mabuɗin Matakai:Yana buƙatar fadada in vitro na adadi mai yawa na sel.
Amfani:Ƙaddamarwa da sauri na hanyoyin kashewa, nau'ikan nau'ikan ƙari.
DC Cell
Yawan Jama'a:Rigakafin tiyata bayan tumor.
Mabuɗin Matakai:Tarin daga jini na gefe.
Amfani:Mafi ƙarfin gabatarwar antigen, daidaitaccen kama siginar ƙari.
CAR-T Cell
Yawan Jama'a:Hematologic ciwace-ciwacen daji, wasu m ciwace-ciwacen daji.
Mabuɗin Matakai:Tarin daga jini na gefe.
Amfani:Madaidaicin ƙwanƙwaran ƙwayoyin ƙari, mallakin ƙwaƙwalwar ajiya.
TO Cell
Yawan Jama'a: Rigakafin tiyata bayan tumor.
Mabuɗin Matakai: Samowa daga ƙwayar ƙwayar cuta ta autologous.
Abũbuwan amfãni: Ƙarfin ikon kashewa, sauƙi shiga cikin ƙananan ƙwayoyin cuta.
Abubuwan Aikace-aikacen Kwayoyin rigakafi
Nasarar magungunan Neurotrophic factor yana ba da ƙarin ƙimar gani akan ƙwayoyin rigakafi.
Harka Daya:
Abubuwan lura na asibiti sun nuna cewa masu fama da ciwon huhu na huhu a ƙarshen zamani, bayan maganin NK cell, sun sami kwanciyar hankali da kula da cututtuka. Sakamakon gwaji ya tabbatar da cewa NK cell immunotherapy za a iya amfani da shi azaman jiyya na adjuvant a cikin kula da masu ciwon huhu a ƙarshen zamani.
Fassarar Gwaji: Manufar ita ce bincika ingancin aikin rigakafi na kwayar cutar NK (HANK) da ke aiki sosai a cikin marasa lafiyan ciwon huhu na ƙarshen zamani. Marasa lafiya goma sha uku (maza 8, mata 5) tare da matsakaicin shekaru 57.3 shekaru, waɗanda aka gano tare da adenocarcinoma (n=12) ko squamous cell carcinoma (n=1), an haɗa su. An gano matakan IV, III, da II a cikin 10, 2, da 1 marasa lafiya (s), bi da bi. Kwayoyin mononuclear sun ware daga marasa lafiya, kuma an fadada ƙwayoyin NK.
Amfani: Kowane majiyyaci ya karɓi aƙalla hanya ɗaya (kowace hanya ta haɗa da infusions guda uku, tare da kowane jiko na dindindin a cikin mintuna 30). Jiyya na wata-wata bai wuce darussa uku ba. Kowace hanya ta ƙunshi infusions guda uku a jere, yana ɗaukar kwanaki uku (kimanin 3-5 × 10 ^ 9 HANK Kwayoyin an tattara su a cikin jakar jini kowace rana, tare da ƙwayar jiko na kimanin 2 × 10 ^ 7 / mL). An auna sassan Lymphocyte, samar da cytokine, da kuma maganganun antigen carcinoembryonic (CEA) da thymidine kinase 1 (TK1) kafin jiyya da kuma bayan jiko na ƙarshe.
Sakamako: Ba a lura da illa ba. Bayan bin watanni 3, adadin marasa lafiya da ke da kwanciyar hankali da ci gaba da cututtuka sun kasance 84.6% da 15.4%, bi da bi. Bugu da ƙari, matakan IFN-γ sun ƙaru sosai bayan jiyya, kuma matakan CEA sun ragu sosai. Gabaɗayan aikin rigakafi na marasa lafiya da ke karɓar maganin tantanin halitta na NK ya kasance barga.
A cikin Nuwamba 1984, Linda Taylor, wata mace mai hidimar sojan ruwa ta Amurka tare da ci gaba mai mahimmanci melanoma, ta shiga cikin gwajin asibiti na ciwon ƙwayar cuta wanda Dr. Steven Rosenberg na Cibiyar Ciwon daji (NCI) ya jagoranta. Ta yi nasarar tsira kuma ta zama majinyata ta farko a duniya da ta warke ta hanyar Neurotrophic factor far.
A cikin 2012, Emily Whitehead mai shekaru 6 ya zama ɗan fari a duniya don yin gwajin gwajin ƙwayoyin cuta. Ta shiga cikin binciken Jami'ar Pennsylvania akan CAR-T far don cutar sankarar lymphoblastic na yara kuma ta sake samun sabuwar rayuwa, tana rayuwa cikin koshin lafiya har yau.
A ranar 5 ga Afrilu, 2016, shirin CCTV-10 mai suna "The Resurrected NK Cells" ya ruwaito cewa Ms. Tang, mai shekaru 58 a lokacin, ta sami ingantacciyar rayuwa da haɓaka rigakafi ta hanyar jini na NK, yana kawar da matsayinta na rashin lafiya.
Bayan shekaru da yawa na ƙoƙarin da ba a yi ba da kuma bincike mai aiki ta ƙarni na masana kimiyya da yawa, fahimtarmu game da rawar da ƙwayoyin rigakafi da bincike kan mahimmancin asibiti na ƙwayoyin rigakafi suna ci gaba da ba da damar ƙwayoyin rigakafi su taka karin matsayi.
Mun yi imanin cewa yayin da bincike da aikace-aikacen ƙwayoyin rigakafi ke ci gaba da zurfafawa, ƙwayoyin rigakafi, a matsayin masu kula da lafiyar ɗan adam, za su ba da gudummawa ga ingantaccen ci gaba na ayyukan lafiyar ɗan adam.